RxDoctor Payments Data

Guillermo Munoz

Internal Medicine · Elizabeth, NJNPI 1023071669

Payments from drug & device makers

$9,469in general payments, 2019–2025

Across 631 payments — averaging $15.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Amgen$1K
  • Boehringer Ingelheim$701
  • AbbVie$632
  • Lilly USA, LLC$628
  • Pfizer$585
  • plus $4K from 38 others

What the payments were for

  • Food & beverage$9,469100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,469 in reported general payments places this provider in the 90th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$39,110
Medicare patients
138
Services billed
489

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin117$154,258
JanuviaSitagliptin Phosphate74$87,515
OzempicSemaglutide60$78,950
RybelsusSemaglutide23$47,623
EliquisApixaban46$46,869
FarxigaDapagliflozin Propanediol34$43,838
LinzessLinaclotide33$31,977
TrulicityDulaglutide11$27,799
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$14,611
Celecoxib279$9,703
ByettaExenatide11$9,616
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$9,160
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$9,057
VascepaIcosapent Ethyl16$7,228
Montelukast Sodium460$5,069

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$701$154,258117 claims
Novo NordiskOzempic, Rybelsus$1,343$126,57383 claims
MerckJanuvia$228$87,51574 claims
AstraZenecaFarxiga, Breztri Aerosphere, Byetta$88$68,06563 claims
PfizerEliquis$585$46,86946 claims
AbbVieLinzess$632$31,97733 claims
Lilly USA, LLCTrulicity$628$27,79911 claims
GSKTrelegy Ellipta$348$9,05714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Elizabeth

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →